Resistance to BRAF/MEK inhibitor treatment occurs in most patients with advanced BRAF^V600-mutant melanoma. Intermittent drug dosing had been proposed as a strategy to circumvent resistance. In a clinical trial published in Nature Medicine, continuous dosing of BRAF/MEK inhibitors produced superior progression-free survival compared to intermittent dosing in BRAF^V600-mutant melanoma patients.

中文翻译：

---

黑色素瘤中BRAK和MEK抑制剂的剂量：暂时不要休息

对BRAF / MEK抑制剂治疗的耐药性在大多数患有BRAF ^V600突变型黑色素瘤的患者中发生。有人提出了间歇给药的方法来规避耐药性。在《自然医学》上发表的一项临床试验中，与BRAF ^V600突变型黑色素瘤患者的间歇给药相比，连续给药BRAF / MEK抑制剂可产生更高的无进展生存期。